CoChat

The DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index; 8 of the 45 sources its claims cite were checked for support.

Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial

Open access
van Raalte, D. H., Brands, M., van der Zijl, N. J., Muskiet, M. H., Pouwels, P. J. W., Ackermans, M. T., Sauerwein, H. P., Serlie, M. J., Diamant, M. · 2011 · Diabetologia

Abstract

AIM/HYPOTHESIS: To assess whether low-dose glucocorticoid treatment induces adverse metabolic effects, as is evident for high glucocorticoid doses. METHODS: In a randomised placebo-controlled double-blind (participants and the investigators who performed the studies and assessed the outcomes were blinded) dose-response intervention study, 32 healthy men (age 22 ± 3 years; BMI 22.4 ± 1.7 kg/m(2)) were allocated to prednisolone 7.5 mg once daily (n = 12), prednisolone 30 mg once daily (n = 12), or placebo (n = 8) for 2 weeks using block randomisation. Main outcome measures were glucose, lipid and protein metabolism, measured by stable isotopes, before and at 2 weeks of treatment, in the fasted state and during a two-step hyperinsulinaemic clamp conducted in the Clinical Research Unit of the Academic Medical Centre, Amsterdam, the Netherlands RESULTS: Prednisolone, compared with placebo, dose dependently and significantly increased fasting plasma glucose levels, whereas only prednisolone 30 mg increased fasting insulin levels (29 ± 15 pmol/l). Prednisolone 7.5 mg and prednisolone 30 mg decreased the ability of insulin to suppress endogenous glucose production (by 17 ± 6% and 46 ± 7%, respectively, vs placebo). Peripheral glucose uptake was not reduced by prednisolone 7.5 mg, but was decreased by prednisolone 30 mg by 34 ± 6% (p < 0.0001). Compared with placebo, prednisolone treatment tended to decrease lipolysis in the fasted state (p = 0.062), but both prednisolone 7.5 mg and prednisolone 30 mg decreased insulin-mediated suppression of lipolysis by 11 ± 5% and 34 ± 6%, respectively. Finally, prednisolone treatment increased whole-body proteolysis during hyperinsulinaemia, which tended to be driven by prednisolone 30 mg (5 ± 2%; p = 0.06). No side effects were reported by the study participants. All participants completed the study and were analysed. CONCLUSIONS/INTERPRETATION: Not only at high doses but also at low doses, glucocorticoid therapy impaired intermediary metabolism by interfering with the metabolic actions of insulin on liver and adipose tissue. These data indicate that even low-dose glucocorticoids may impair glucose tolerance when administered chronically. TRIAL REGISTRATION: ISRCTN83991850.

Overview

CoChat Summary

TL;DR

In healthy men, 2-week prednisolone treatment at 7.5 mg/day impaired insulin suppression of endogenous glucose production and lipolysis, while 30 mg/day additionally reduced peripheral glucose uptake and increased fasting insulin, glucagon and triglycerides. Low-dose glucocorticoids can induce hepatic and adipose tissue insulin resistance even without changes in body composition.

Key findings

  • Prednisolone dose-dependently increased fasting plasma glucose; only prednisolone 30 mg increased fasting insulin levels (29 ± 15 pmol/l) and glucagon, and increased fasting triacylglycerol levels.
  • Insulin suppression of endogenous glucose production was impaired by prednisolone 7.5 mg and 30 mg by 17 ± 6% and 46 ± 7%, respectively, vs placebo; peripheral glucose uptake was not reduced by 7.5 mg but was decreased by 30 mg by 34 ± 6% (p < 0.0001).
  • Prednisolone tended to decrease fasting lipolysis (p = 0.062) but decreased insulin-mediated suppression of lipolysis by 11 ± 5% (7.5 mg) and 34 ± 6% (30 mg); whole-body proteolysis during hyperinsulinaemia increased overall, tending to be driven by 30 mg (5 ± 2%; p = 0.06).
  • Body weight, lean body mass, total fat mass, liver fat content, and visceral/subcutaneous adipose tissue areas were unchanged; all participants completed and were analysed, with one mild gastric discomfort in the 30 mg group and otherwise no treatment-related side effects.

Methods

  • Randomised double-blind placebo-controlled dose–response study: 32 healthy white men (age 22 ± 3 years; BMI 22.4 ± 1.7 kg/m²) were allocated to prednisolone 7.5 mg once daily (n = 12), prednisolone 30 mg once daily (n = 12), or placebo (n = 8) for 14 days using block randomisation.
  • Glucose, lipid and protein metabolism were measured with stable isotopes ([6,6-²H₂]glucose, [1,1,2,3,3-²H₅]glycerol, L-[1-¹³C]valine) before and at 2 weeks of treatment, in the fasted state and during a two-step hyperinsulinaemic–euglycaemic clamp; body composition was assessed by DEXA, MRI and ¹H-MRS.
  • Between-group changes from baseline were tested by Kruskal–Wallis; significant findings were followed by Mann–Whitney U testing with Bonferroni correction, with p < 0.05 considered significant.

Limitations

  • Stated: clamp tests were performed under non-steady-state prednisolone levels because prednisolone has a t½ of 4–6 h, so the final part of the clamp may have occurred under lower prednisolone levels; plasma prednisolone may also poorly reflect genomic actions.
  • Stated: participants were healthy volunteers, not patients with chronic inflammatory diseases; because systemic inflammation also impairs insulin sensitivity, the combined anti-inflammatory and metabolic effects of glucocorticoids could be more complex in clinical populations.
  • Evident: the sample was small (n = 32 total; placebo n = 8), included only healthy white men aged 18–35 with BMI 20–25 kg/m², and treatment lasted only 2 weeks, limiting generalisability to women, older adults, obese or patient populations, and longer-term outcomes.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s00125-011-2174-9

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 The effects of prednisolone treatment on glucose metabolism. a Prednisolone treatment increased basal EGP. This was driven by prednisolone 30 mg once daily. b EGP during insulin infusion was dose dependently increased by prednisolone treatment. c The rate of glucose disappearance was decreased by prednisolone 30 mg, but not by prednisolone 7.5 mg once daily. Data represent means ± SEM. Black bars, before treatment; white bars, day 14 of treatment. Between-group changes from baseline were tested by Kruskal–Wallis (indicated by top line). Post hoc tests were done by Mann–Whitney U with Bonferroni correction for multiple testing (indicated by line with brackets). **p < 0.01; ***p < 0.001. PLB, placebo
Fig. 1 The effects of prednisolone treatment on glucose metabolism. a Prednisolone treatment increased basal EGP. This was driven by prednisolone 30 mg once daily. b EGP during insulin infusion was dose dependently increased by prednisolone treatment. c The rate of glucose disappearance was decreased by prednisolone 30 mg, but not by prednisolone 7.5 mg once daily. Data represent means ± SEM. Black bars, before treatment; white bars, day 14 of treatment. Between-group changes from baseline were tested by Kruskal–Wallis (indicated by top line). Post hoc tests were done by Mann–Whitney U with Bonferroni correction for multiple testing (indicated by line with brackets). **p < 0.01; ***p < 0.001. PLB, placeboCC BY-NC · PubMed Central
Fig. 2 The effects of prednisolone treatment on glycerol appearance (R a). a Prednisolone treatment tended to decrease basal lipolysis, which seemed caused by the prednisolone 30 mg once daily dose. b During insulin infusion targeted at 200 pmol/l, prednisolone treatment dose dependently increased glycerol turnover. This reached significance for prednisolone 30 mg, but remained a trend for prednisolone 7.5 mg once daily. c At higher insulin (600 pmol/l) during step 2 of the clamp, a similar pattern was observed, with a dose-dependent increase of whole-body lipolysis with prednisolone treatment. Data represent means ± SEM. Black bars, before treatment; white bars, day 14 of treatment. Between-group changes from baseline were tested by Kruskal–Wallis (indicated by top line). Post hoc tests were done by Mann–Whitney U with Bonferroni correction for multiple testing (indicated by line with brackets). *p < 0.05; **p < 0.01; † p = 0.062; ‡ p = 0.09. PLB, placebo
Fig. 2 The effects of prednisolone treatment on glycerol appearance (R a). a Prednisolone treatment tended to decrease basal lipolysis, which seemed caused by the prednisolone 30 mg once daily dose. b During insulin infusion targeted at 200 pmol/l, prednisolone treatment dose dependently increased glycerol turnover. This reached significance for prednisolone 30 mg, but remained a trend for prednisolone 7.5 mg once daily. c At higher insulin (600 pmol/l) during step 2 of the clamp, a similar pattern was observed, with a dose-dependent increase of whole-body lipolysis with prednisolone treatment. Data represent means ± SEM. Black bars, before treatment; white bars, day 14 of treatment. Between-group changes from baseline were tested by Kruskal–Wallis (indicated by top line). Post hoc tests were done by Mann–Whitney U with Bonferroni correction for multiple testing (indicated by line with brackets). *p < 0.05; **p < 0.01; † p = 0.062; ‡ p = 0.09. PLB, placeboCC BY-NC · PubMed Central
Fig. 3 The effect of prednisolone treatment on valine appearance (R a). a Valine turnover in the basal state was not affected by prednisolone treatment. b Overall, valine turnover was increased during step 1 of the hyperinsulinaemic–euglycaemic clamp by prednisolone treatment. This seemed driven by prednisolone 30 mg in post hoc analysis, but failed to reach statistical significance. c A similar pattern was observed during step 2 of the clamp, where overall prednisolone treatment increased valine turnover; however, in post hoc testing, no significance was reached for either dose compared with placebo. Data represent means ± SEM. Black bars, before treatment; white bars, day 14 of treatment. Between-group changes from baseline were tested by Kruskal–Wallis (indicated by top line). Post hoc tests were done by Mann–Whitney U with Bonferroni correction for multiple testing (indicated by line with brackets). *p < 0.05; † p = 0.06. PLB, placebo
Fig. 3 The effect of prednisolone treatment on valine appearance (R a). a Valine turnover in the basal state was not affected by prednisolone treatment. b Overall, valine turnover was increased during step 1 of the hyperinsulinaemic–euglycaemic clamp by prednisolone treatment. This seemed driven by prednisolone 30 mg in post hoc analysis, but failed to reach statistical significance. c A similar pattern was observed during step 2 of the clamp, where overall prednisolone treatment increased valine turnover; however, in post hoc testing, no significance was reached for either dose compared with placebo. Data represent means ± SEM. Black bars, before treatment; white bars, day 14 of treatment. Between-group changes from baseline were tested by Kruskal–Wallis (indicated by top line). Post hoc tests were done by Mann–Whitney U with Bonferroni correction for multiple testing (indicated by line with brackets). *p < 0.05; † p = 0.06. PLB, placeboCC BY-NC · PubMed Central

Verification

Claims the paper makes

7 Valid · 1 Not valid · 20 Not checked · 64 Own results and interpretations

26 more claims

Create a free account to see all 92 claims and to verify the 2 references still open.

See all claims — free account
  • Probably not a substantial claim. 28
  • It may state two separate claims as one. 41

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 52 references

Cited by

See all 110

Metadata

Authors
van Raalte, D. H., Brands, M., van der Zijl, N. J., Muskiet, M. H., Pouwels, P. J. W., Ackermans, M. T., Sauerwein, H. P., Serlie, M. J., & Diamant, M.
Affiliations
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
Venue
Diabetologia
Published
2011-05-12
Volume
54
Issue
8
Pages
2103-2112
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
OpenAlex
W2120890763
Cited by
109
References
52
Citations by year
2026: 4 · 2025: 8 · 2024: 3 · 2023: 6 · 2022: 7 · 2021: 9 · 2020: 7 · 2019: 9 · 2018: 10 · 2017: 1 · 2016: 4 · 2015: 10 · 2014: 5 · 2013: 12 · 2012: 9
FWCI
8.12
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Diabetologia (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Research Publications (Maastricht University) (submittedVersion, cc-by-nc)
  • Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion, other-oa)
  • Research Publications (Maastricht University) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
  • Eli Lilly and Company
  • Amylin Pharmaceuticals
  • GlaxoSmithKline
  • Sanofi
  • Vrije Universiteit Amsterdam
  • Novo Nordisk
  • Top Institute Pharma
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
prednisolone, low-dose glucocorticoids, intermediary metabolism, glucose metabolism, insulin resistance, lipolysis, hyperinsulinemic-euglycemic clamp, dose-response relationship, prednisolone dose, healthy men, stable isotope tracer infusion, fasting blood glucose, peripheral glucose uptake, lipid metabolism, protein metabolism, metabolic side effects
MeSH terms
Adult, Biological Transport, Blood Glucose, Double-Blind Method, Glucocorticoids, Humans, Insulin, Lipolysis, Male, Prednisolone, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial. https://app.cochat.ai/papers/10.1007/s00125-011-2174-9
The paper
van Raalte, D. H., Brands, M., van der Zijl, N. J., Muskiet, M. H., Pouwels, P. J. W., Ackermans, M. T., Sauerwein, H. P., Serlie, M. J., & Diamant, M. (2011). Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial. Diabetologia. https://doi.org/10.1007/s00125-011-2174-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.